NO944912L - Fremgangsmåte for å öke makrofagfunksjonen - Google Patents
Fremgangsmåte for å öke makrofagfunksjonenInfo
- Publication number
- NO944912L NO944912L NO944912A NO944912A NO944912L NO 944912 L NO944912 L NO 944912L NO 944912 A NO944912 A NO 944912A NO 944912 A NO944912 A NO 944912A NO 944912 L NO944912 L NO 944912L
- Authority
- NO
- Norway
- Prior art keywords
- macrophage function
- steps
- increase macrophage
- increase
- hexamethyleneamino
- Prior art date
Links
- 210000002540 macrophage Anatomy 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/170,605 US5672610A (en) | 1993-12-21 | 1993-12-21 | Methods of increasing macrophage function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO944912D0 NO944912D0 (no) | 1994-12-19 |
| NO944912L true NO944912L (no) | 1995-06-22 |
Family
ID=22620563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO944912A NO944912L (no) | 1993-12-21 | 1994-12-19 | Fremgangsmåte for å öke makrofagfunksjonen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5672610A (enExample) |
| EP (1) | EP0659425A1 (enExample) |
| JP (1) | JPH07215861A (enExample) |
| KR (1) | KR950016721A (enExample) |
| CN (1) | CN1049818C (enExample) |
| AU (1) | AU693127B2 (enExample) |
| CA (1) | CA2138492A1 (enExample) |
| CZ (1) | CZ320794A3 (enExample) |
| HU (1) | HUT71475A (enExample) |
| IL (1) | IL112032A (enExample) |
| NO (1) | NO944912L (enExample) |
| NZ (1) | NZ270165A (enExample) |
| PH (1) | PH31267A (enExample) |
| RU (1) | RU94044455A (enExample) |
| TW (1) | TW321599B (enExample) |
| ZA (1) | ZA9410081B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| IL146284A0 (en) | 1999-05-04 | 2002-07-25 | Strakan Ltd | Androgen glycosides and pharmaceutical compositions containing the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| JPS62201819A (ja) * | 1985-11-13 | 1987-09-05 | Res Dev Corp Of Japan | 免疫不全症処置剤 |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
-
1993
- 1993-12-21 US US08/170,605 patent/US5672610A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 HU HU9403659A patent/HUT71475A/hu unknown
- 1994-12-19 IL IL11203294A patent/IL112032A/en not_active IP Right Cessation
- 1994-12-19 CZ CZ943207A patent/CZ320794A3/cs unknown
- 1994-12-19 AU AU81551/94A patent/AU693127B2/en not_active Ceased
- 1994-12-19 JP JP6314538A patent/JPH07215861A/ja active Pending
- 1994-12-19 KR KR1019940034912A patent/KR950016721A/ko not_active Withdrawn
- 1994-12-19 RU RU94044455/14A patent/RU94044455A/ru unknown
- 1994-12-19 NZ NZ270165A patent/NZ270165A/xx unknown
- 1994-12-19 PH PH49584A patent/PH31267A/en unknown
- 1994-12-19 CA CA002138492A patent/CA2138492A1/en not_active Abandoned
- 1994-12-19 ZA ZA9410081A patent/ZA9410081B/xx unknown
- 1994-12-19 TW TW083111833A patent/TW321599B/zh active
- 1994-12-19 NO NO944912A patent/NO944912L/no unknown
- 1994-12-19 CN CN94119737A patent/CN1049818C/zh not_active Expired - Fee Related
- 1994-12-19 EP EP94309483A patent/EP0659425A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NO944912D0 (no) | 1994-12-19 |
| HU9403659D0 (en) | 1995-02-28 |
| AU693127B2 (en) | 1998-06-25 |
| HUT71475A (en) | 1995-11-28 |
| JPH07215861A (ja) | 1995-08-15 |
| IL112032A (en) | 1999-03-12 |
| US5672610A (en) | 1997-09-30 |
| CA2138492A1 (en) | 1995-06-22 |
| PH31267A (en) | 1998-06-18 |
| EP0659425A1 (en) | 1995-06-28 |
| CZ320794A3 (en) | 1995-09-13 |
| NZ270165A (en) | 1997-08-22 |
| RU94044455A (ru) | 1996-10-10 |
| AU8155194A (en) | 1995-06-29 |
| CN1108092A (zh) | 1995-09-13 |
| ZA9410081B (en) | 1996-06-19 |
| CN1049818C (zh) | 2000-03-01 |
| KR950016721A (ko) | 1995-07-20 |
| IL112032A0 (en) | 1995-03-15 |
| TW321599B (enExample) | 1997-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO944911L (no) | Ikke-peptid-takykininreseptorantagonister | |
| NO944928L (no) | Fremgangsmåter for inhibering av Alzheimers sykdom | |
| NO944914L (no) | Fremgangsmåte for å inhibere autoimmunsykdommer | |
| MY132056A (en) | Methods of inhibiting physiological conditions associated with an excess of neuropeptide y. | |
| NO944919L (no) | Fremgangsmåte for å inhibere atrofi av huden eller vagina | |
| NO944927L (no) | Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom | |
| NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
| TW352382B (en) | Substituted sulfonimidamides, processes for their preparation, their use as a medicament of diagnostic, and medicament comprising them | |
| NO973635L (no) | Fremgangsmåte for hemming av celle-celle adhesjon | |
| NO944926L (no) | Fremgangsmåter for å inhibere myeloperoksidaseaktivitet | |
| DK0651999T3 (da) | Fremgangsmåder til inhibering af livmoderfibrose | |
| MX9701325A (es) | Metodos para inhibir la mucositis ulcerativa. | |
| MX9701360A (es) | Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. | |
| NO944930L (no) | Hemming av dysfunksjonell uterin blödning | |
| NO944924L (no) | Fremgangsmåter for inhibering av Turner's syndrom | |
| DK0659427T3 (da) | 2-Phenyl-3-azoylbenzothiophener til forøgelse af thrombomodulinekspression | |
| ATE82262T1 (de) | Piperidin-derivate. | |
| NO944931L (no) | Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet | |
| NO972887L (no) | Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel | |
| NO944923L (no) | Hemming av vektökning eller indusering av vekttap | |
| NO975580L (no) | Fremgangsmåte for å inhibere melanom | |
| NO973367L (no) | Fremgangsmåte for å inhibere miljömessige östrogen | |
| NO973609L (no) | Fremgangsmåte for å inhibere effektene av IL-6 | |
| NO981578L (no) | FremgangsmÕte for hemming av plasminogenaktivatorhemmer I | |
| NO944577L (no) | Hemming av effekten av amyloidogene proteiner |